terminate our product development or commercialization efforts.-4-Table of Contents•We have not obtained agreement with the FDA, the EMA or other regulatory authorities on the design of our Phase 3 development program.•Clinical drug development is a lengthy and expensive process with an uncertain outcome, and positive results from Phase 1 and Phase 2a clinical trials
subsequent clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize AKB-6548.•Even if we receive regulatory approval for our product candidates, such drug products will be subject to ongoing regulatory review, which may result in
cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.We intend to use the net proceeds from this offering to continue clinical development of AKB-6548 in patients with anemia secondary to CKD, including the preparation for and initiation of the Phase 3
approximately $14.4 million, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.As of December 31, 2013ActualPro formaPro forma asadjusted(in thousands)Balance Sheet Data:Cash and cash equivalents$21,215$21,215$91,849Working capital29,52929,529100,163Total assets34,66534,665105,299Redeemable convertible preferred stock157,827——Deficit accumulated during the development stage(127,072)(63,707)(63,707)Total stockholders’ (deficit) equity(127,072)30,755101,389-10-Table of ContentsRisk FactorsInvesting in our common stock involves a high degree of risk.
We anticipate that our expenses will increase significantly if and as we:•continue our Phase 2b trial and prepare for a future Phase 3 development program of AKB-6548 for the treatment of anemia secondary to CKD;•seek regulatory approvals for our product candidates that successfully complete clinical studies;•have our product candidates manufactured for clinical trials and for commercial sale;•establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;•initiate additional preclinical, clinical or other studies for AKB-6548, AKB-6899 and other product candidates that we may develop or acquire;•seek to discover and develop additional product candidates;•acquire or in-license other commercial products, product candidates and technologies;•make royalty, milestone or other payments under any future in-license agreements;•maintain, protect and expand our intellectual property portfolio;•attract and retain skilled personnel; and-11-Table of Contents•create additional infrastructure to support our operations as a public company.Because of the numerous risks and uncertainties associated with
FDA, the EMA or other regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our product candidates, our expenses could increase.The net losses we incur may fluctuate significantly from quarter
necessary to successfully complete the development and commercialization of our product candidates.Our future capital requirements depend on many factors, including:•the rate of progress, results and cost of completing our Phase 2b clinical trial of AKB-6548 and our operating costs incurred as we conduct these
Phase 3 development program of AKB-6548;•assuming favorable clinical results, the cost, timing and outcome of our efforts to obtain marketing approval for AKB-6548 in the United States, Europe
and in other jurisdictions, including to fund the preparation and filing of regulatory submissions for AKB-6548 with the FDA, the EMA and other regulatory authorities;•the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for AKB-6899 and any other product candidates
that we may develop or acquire;-12-Table of Contents•the timing of, and the costs involved in, obtaining regulatory approvals for AKB-6899 if clinical trials are successful;•the cost and timing of future commercialization activities for our products, if any of our product candidates are approved for marketing, including
establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates.Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to product
Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue.We intend to rely on third parties to conduct some or all
therapies and of physicians to prescribe new therapies;•the cost, safety and efficacy of treatment in relation to alternative treatments;•the availability of adequate coverage and reimbursement by third party payors and government authorities;•the ability to contract with dialysis providers;•relative convenience and ease of administration;•the prevalence and severity of adverse side effects;•the effectiveness of our sales and marketing efforts; and•the restrictions on the use of our products together with other medications, if any.For example, two of the largest operators of dialysis clinics in the United
continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:•the demand for any drug products for which we may obtain regulatory approval;•our ability to set a price that we believe is fair for our products;•our ability to obtain coverage and reimbursement approval for a product;•our ability to generate revenues and achieve or maintain profitability; and•the level of taxes that we are required to pay.If our product candidates obtain marketing approval, we will be subject
timing of our submission of an NDA for AKB-6548;•our plans to commercialize AKB-6548, if it is approved;•our development plans with respect to AKB-6899;•the timing or likelihood of regulatory filings and approvals, including any required post-marketing testing or any labeling and other restrictions;•the implementation of our business model and strategic plans for our business, product candidates and technology;•our commercialization, marketing and manufacturing capabilities and strategy;•the rate and degree of market acceptance and clinical utility of our products;•our competitive position;•our intellectual property position;•developments and projections relating to our competitors and our industry;•our ability to establish collaborations or obtain additional funding;•our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;•our expectations related to the use of proceeds from this offering; and•our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.We may not actually achieve the plans, intentions or expectations disclosed
one or more collaborators to commercialize the product candidate in additional markets.Since our inception in 2007, we have devoted substantially all of our resources to our development efforts relating to AKB-6548, including preparing for and conducting clinical studies of AKB-6548,